Kegg medicus dgroup
| DG01635 | |
| DG番号 | DG01635 |
| 分類 | DGroup |
| 名称 | CYP3A4 inducer TYPE Metabolism |
| ステム | - |
| 構造式 |  |
| メンバー | DG00011 Dexamethasone D00292 Dexamethasone (JP18/USP/INN) D00975 Dexamethasone sodium phosphate (JAN/USP) D01510 Dexamethasone metasulfobenzoate sodium (JAN) D01615 Dexamethasone palmitate (JAN) D01632 Dexamethasone dipropionate (USAN); Dexamethasone propionate (JAN) D01948 Dexamethasone valerate (JAN) D02174 Dexamethasone acetate (JAN/USP) D02591 Dexamethasone acefurate (USAN/INN) D02592 Dexamethasone beloxil (USAN) D07073 Dexamethasone cipecilate (JAN/INN) D07796 Dexamethasone 21-acetate D07797 Dexamethasone isonicotinate D07798 Dexamethasone sodium hemisulfate D07799 Dexamethasone 21-tebutate D07800 Dexamethasone 21-valerate D07801 Dexamethasone phenylpropionate D07802 Dexamethasone phosphate DG00066 Aprepitant D02968 Aprepitant (JAN/USP/INN) D10895 Fosaprepitant (INN) D06597 Fosaprepitant dimeglumine (USAN); Fosaprepitant meglumine (JAN) D02554 Rifaximin (JAN/USAN/INN) D10003 Hemin (JAN) DG00266 Bosentan D07538 Bosentan (INN) D01227 Bosentan (USAN); Bosentan hydrate (JAN) DG00639 Rifampicin D00211 Rifampin (USP); Rifampicin (JP18/INN) D08479 Rifampicin sodium D00879 Rifapentine (USAN/INN) D00896 Efavirenz (JAN/USP/INN) D04112 Etravirine (JAN/USAN/INN) D10093 Asunaprevir (JAN/USAN) D10882 Daclatasvir, asunaprevir and beclabuvir D09996 Vemurafenib (JAN/USAN/INN) DG00721 Dabrafenib D10064 Dabrafenib (USAN) D10104 Dabrafenib mesylate (USAN); Dabrafenib mesilate (JAN) D11040 Apalutamide (JAN/INN) DG00847 Fosphenytoin D07993 Fosphenytoin (INN) D02096 Fosphenytoin sodium (USP) D07595 Fosphenytoin sodium hydrate (JAN) D00252 Carbamazepine (JP18/USP/INN) DG00848 Eslicarbazepine D09215 Eslicarbazepine (USAN/INN) D09612 Eslicarbazepine acetate (USAN) D01832 Modafinil (JAN/USP/INN) DG00999 Methadone D08195 Methadone (BAN) D02102 Methadone hydrochloride (JAN/USP) D03669 Deferasirox (JAN/USAN/INN) |
| 上位グループ | Metabolizing enzyme inducer DG02853 CYP3A/CYP3A4 inducer |
| 注釈1 | - |
| 注釈2 | - |